FOLETTA MARK G 4

What Happened

• Mark G. Foletta, a director of Enanta Pharmaceuticals, was granted a derivative award covering 20,000 shares on March 11, 2026. The reported acquisition price is $0.00 (derivative), so the reported immediate cash value is $0. This filing reflects an award/grant (code A), not a market purchase or sale.

Key Details

• Transaction date: 2026-03-11; Filing date: 2026-03-13 (filed within the typical 2-business-day Form 4 window).
• Award: 20,000 derivative shares (option) at $0.00 reported price.
• Shares owned after transaction: Not specified in the provided filing details.
• Footnote: The option becomes exercisable monthly in substantially equal installments over one year beginning March 11, 2026; the final monthly installment vests no later than the nearest Nasdaq trading day before the 2027 annual meeting.
• No 10b5-1 plan, tax withholding, cashless exercise, or sale of shares reported in this filing.

Context

• This is a compensation award (an option grant) that vests over time; it does not represent an immediate purchase or sale. Such grants indicate potential future ownership if and when options vest and are exercised, but they do not by themselves signal an immediate change in insider shareholding or market activity.